Therefore, TKIs can be exploited to overcome resistance by increasing the intracellular concentration of P-gp and/or ABCG2 substrate anticancer drugs in cancer cells, tissues or tumors that express high levels of these transporters [29]. Here, ABCG2 is linked to cancer.